Skip to main content

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Completed · Phase 2 · NCT06097299

Conditions: Respiratory Syncytial Virus

At a glance

Research payments reported, 2025
$795,479
U.S. investigators named
43
Sites paid
25
Planned or actual enrollment
349

About the trial

Sponsor
ModernaTX, Inc.
Tested
mRNA-1345 (biological), Placebo (biological)
Dates
Started 2023-10-24; completion 2025-06-27
Results posted
Yes

Part A: The purpose is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1345 in children aged 2 to \<5 years (Cohort 1) and in children at high risk of respiratory syncytial virus (RSV) disease 5 to \<18 years of age (Cohort 2) to inform the dose level selection for the next phase of development (Phase 3). Part B: The purpose is to provide surveillance for RSV disease for the next RSV season (6 months after re-enrollment) and safety follow-up for Cohort 1 participants that were enrolled and dosed in Part A.

From ClinicalTrials.gov, last updated 2026-08-18. Full record, eligibility and contacts (opens in a new tab)

Industry funding

ModernaTX, Inc. reported $795,479 in research payments for this study in 2025 (479 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Velocity Clinical Research Inc $155,452
  • West Houston Clinical Research Service $90,933
  • Elias Research Associates LLC $88,819
  • Dynamed Clinical Research LP $70,131
  • Clinical Research Prime Idaho Falls LLC $60,201
  • Strong Memorial Hospital, NY $52,282
  • Clinical Research PArtners LLC $37,281
  • Dynamed Philadelphia LLC $31,001
  • Enso Mb LLC D B A Victoria Clinical Research Group $27,220
  • $24,176
  • Javara Inc $23,285
  • Elligo Health Research Inc $17,251
  • Children's Hospital of Philadelphia, PA $14,983
  • University Clinical Research Deland LLC $13,973
  • Acrc Trials $11,822
  • Clinical Research Institute Inc $11,013
  • Med Care Research Corp $10,784
  • Rex Clinical Trials LLC $10,100
  • Tribe Clinical Research LLC $7,830
  • Sec Clinical Research LLC $6,848
  • Sandhill Research LLC $6,750
  • Cenexel Iresearch LLC $6,230
  • Alliance for Multispecialty Research LLC $5,670
  • Coastalpediatricresearch $4,050
  • Headlands Horizons LLC $3,894
  • Ark Clinical Research LLC $3,500

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.